← Leaderboards
Michael A Hollingsworth
University Of Nebraska Medical Center
$34,707,253
Attributed
$36,613,216
Total exposure
24
Grants
21
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.4M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$59,044,646 · 26
By mechanism
P50$28,393,949 · 9
U01$20,538,295 · 3
R01$4,439,983 · 4
P30$1,987,206 · 4
U54$1,822,016 · 3
P01$1,566,197 · 1
Top collaborators
- Surinder Kumar Batra6 shared
- Joshua M Mammen1 shared
Most similar at University Of Nebraska Medical Center
Same institution · by research overlap
- Moorthy P. Ponnusamy$2,721,536
- James Eudy$2,606,908
- Simon Sherman$5,087,859
- Pi-Wan Cheng$3,131,854
- Maneesh Jain$6,905,007
Others in their field
Top investigators on “Malignant Neoplasm Of Pancreas”
- David Heimbrook · Leidos Biomedical Research, Inc.$73,277,592
- Anirban Maitra · Johns Hopkins University$43,028,398
- Walter John Curran · Thomas Jefferson University$26,641,549
- Surinder Kumar Batra · University Of Pittsburgh At Pittsburgh$26,074,679
- Robert E Reiter · University Of California Los Angeles$21,473,394
- Monica M Bertagnolli · Strang Cancer Prevention Center$20,383,871
Research focus
Malignant Neoplasm Of PancreasMalignant NeoplasmsTumorPancreasBaseNeoplasm MetastasisProgramsMolecularAdenocarcinomaTissuesResearch PersonnelSamplingMucinsLaboratoriesGlycoproteinsBiologicalTumor ProgressionPancreatic NeoplasmAffectMalignant - DescriptorNeoplastic CellOrganAutopsyCells
Grant awards (130)
Pancreatic Cancer Detection Consortium$817,862
U01 · FY2025 · CA · contact PI
Porcine Platforms For Technology Development In Pancreatic Cancer$635,749
R01 · FY2025 · CA · contact PI
MUC1 in Therapy Resistance$339,853
U54 · FY2025 · CA · contact PI
Shared Resource Management$83,694
P30 · FY2025 · CA · contact PI
Pancreatic Cancer Detection Consortium$776,970
U01 · FY2024 · CA · contact PI
MUC1 in Therapy Resistance$247,902
U54 · FY2024 · CA · contact PI
Shared Resource Management$77,503
P30 · FY2024 · CA · contact PI
Pancreatic Cancer Detection Consortium$801,505
U01 · FY2023 · CA · contact PI
MUC1 in Therapy Resistance$260,950
U54 · FY2023 · CA · contact PI
Shared Resource Management$77,504
P30 · FY2023 · CA · contact PI
Pancreatic Cancer Detection Consortium$857,987
U01 · FY2022 · CA · contact PI
MUC1 in Therapy Resistance$332,343
U54 · FY2022 · CA · contact PI
Project 2: Biological Effects of Patient-derived Mutations in MUC16 on PC Metastasis$310,110
P01 · FY2022 · CA · contact PI
Shared Resource Management$77,504
P30 · FY2022 · CA · contact PI
Pancreatic Cancer Detection Consortium$1,769,048
U01 · FY2021 · CA · contact PI
Project 2: Biological Effects of Patient-derived Mutations in MUC16 on PC Metastasis$316,438
P01 · FY2021 · CA · contact PI
Shared Resource Management$77,293
P30 · FY2021 · CA · contact PI
Pancreatic Cancer Detection Consortium$1,775,773
U01 · FY2020 · CA · contact PI
Project 2: Biological Effects of Patient-derived Mutations in MUC16 on PC Metastasis$316,438
P01 · FY2020 · CA · contact PI
Molecular Biology (MB)$162,520
P30 · FY2020 · CA · contact PI
Pancreatic Cancer Detection Consortium$1,729,725
U01 · FY2019 · CA · contact PI
Project 2: Biological Effects of Patient-derived Mutations in MUC16 on PC Metastasis$306,946
P01 · FY2019 · CA · contact PI
Molecular Biology (MB)$162,520
P30 · FY2019 · CA · contact PI
SPORE in Pancreatic Cancer$2,300,000
P50 · FY2018 · CA · contact PI
Pancreatic Cancer Detection Consortium$1,783,224
U01 · FY2018 · CA · contact PI
Inhibition of CDK5 as a Treatment for Pancreatic Cancer$367,223
P50 · FY2018 · CA · contact PI
Project 2: Biological Effects of Patient-derived Mutations in MUC16 on PC Metastasis$316,265
P01 · FY2018 · CA · contact PI
Administrative Core$251,906
P50 · FY2018 · CA · contact PI
Molecular Biology (MB)$162,114
P30 · FY2018 · CA · contact PI
Career Development Program$135,097
P50 · FY2018 · CA · contact PI
Developmental Research Program$95,439
P50 · FY2018 · CA · contact PI
SPORE in Pancreatic Cancer$2,379,383
P50 · FY2017 · CA · contact PI
Pancreatic Cancer Detection Consortium$1,761,905
U01 · FY2017 · CA · contact PI
Inhibition of CDK5 as a Treatment for Pancreatic Cancer$379,900
P50 · FY2017 · CA · contact PI
Administrative Core$260,600
P50 · FY2017 · CA · contact PI
Molecular Biology (MB)$160,057
P30 · FY2017 · CA · contact PI
Career Development Program$139,758
P50 · FY2017 · CA · contact PI
Developmental Research Program$98,730
P50 · FY2017 · CA · contact PI
SPORE in Pancreatic Cancer$2,162,000
P50 · FY2016 · CA · contact PI
SPORE in Pancreatic Cancer$500,000
P50 · FY2016 · CA · contact PI
Inhibition of CDK5 as a Treatment for Pancreatic Cancer$364,128
P50 · FY2016 · CA · contact PI
Administrative Core$243,665
P50 · FY2016 · CA · contact PI
Molecular Biology (MB)$159,304
P30 · FY2016 · CA · contact PI
Career Development Program$114,160
P50 · FY2016 · CA · contact PI
SPORE in Pancreatic Cancer$100,000
P50 · FY2016 · CA · contact PI
Developmental Research Program$81,059
P50 · FY2016 · CA · contact PI
SPORE in Pancreatic Cancer$2,185,000
P50 · FY2015 · CA · contact PI
Inhibition of CDK5 as a Treatment for Pancreatic Cancer$325,622
P50 · FY2015 · CA · contact PI
Administrative Core$247,178
P50 · FY2015 · CA · contact PI
Early Diagnosis of Pancreatic Cancer$197,326
U01 · FY2015 · CA · contact PI
Lymphangiogeneis and Metastasis During Pancreatic Cancer Progression$160,407
U54 · FY2015 · CA · contact PI
Career Development Program$146,908
P50 · FY2015 · CA · contact PI
Developmental Research Program$139,135
P50 · FY2015 · CA · contact PI
SPORE in Pancreatic Cancer$2,162,000
P50 · FY2014 · CA · contact PI
Early Diagnosis of Pancreatic Cancer$555,169
U01 · FY2014 · CA · contact PI
Inhibition of CDK5 as a Treatment for Pancreatic Cancer$364,128
P50 · FY2014 · CA · contact PI
Administrative Core$243,666
P50 · FY2014 · CA · contact PI
Lymphangiogeneis and Metastasis During Pancreatic Cancer Progression$160,869
U54 · FY2014 · CA · contact PI
Career Development Program$114,162
P50 · FY2014 · CA · contact PI
Developmental Research Program$81,059
P50 · FY2014 · CA · contact PI
Early Diagnosis of Pancreatic Cancer$549,264
U01 · FY2013 · CA · contact PI
Lymphangiogeneis and Metastasis During Pancreatic Cancer Progression$146,121
U54 · FY2013 · CA · contact PI
SPORE in Gastrointestinal Cancer$1,066,666
P50 · FY2012 · CA · contact PI
Early Diagnosis of Pancreatic Cancer$594,573
U01 · FY2012 · CA · contact PI
Studies on the Post-translational processing of MUC1$255,282
R01 · FY2012 · CA · contact PI
Lymphangiogeneis and Metastasis During Pancreatic Cancer Progression$173,571
U54 · FY2012 · CA · contact PI
P-1: Immunotherapy of Pancreatic Adenocarcinoma$130,396
P50 · FY2012 · CA · contact PI
CA: Administration Core$120,630
P50 · FY2012 · CA · contact PI
A novel combination therapy for the treatment of Pancreatic adenocarcinoma$74,250
R03 · FY2012 · CA · contact PI
SPORE in Gastrointestinal Cancer$1,013,333
P50 · FY2011 · CA · contact PI
Early Diagnosis of Pancreatic Cancer$606,189
U01 · FY2011 · CA · contact PI
Autoantibodies Against Glycopeptide Epitopes as Serum Biomarkers of Cancer$277,966
U01 · FY2011 · CA · contact PI
Studies on the Post-translational processing of MUC1$255,282
R01 · FY2011 · CA · contact PI
P-1: Immunotherapy of Pancreatic Adenocarcinoma$124,363
P50 · FY2011 · CA · contact PI
CA: Administration Core$86,034
P50 · FY2011 · CA · contact PI
A novel combination therapy for the treatment of Pancreatic adenocarcinoma$74,250
R03 · FY2011 · CA · contact PI
SPORE in Gastrointestinal Cancer$1,066,666
P50 · FY2010 · CA · contact PI
Early Diagnosis of Pancreatic Cancer$673,656
U01 · FY2010 · CA · contact PI
Autoantibodies Against Glycopeptide Epitopes as Serum Biomarkers of Cancer$284,750
U01 · FY2010 · CA · contact PI
Studies on the Post-translational processing of MUC1$263,177
R01 · FY2010 · CA · contact PI
P-1: Immunotherapy of Pancreatic Adenocarcinoma$135,215
P50 · FY2010 · CA · contact PI
CA: Administration Core$125,214
P50 · FY2010 · CA · contact PI
SPORE in Gastrointestinal Cancer$1,066,666
P50 · FY2009 · CA · contact PI
Early Diagnosis of Pancreatic Cancer$513,183
U01 · FY2009 · CA · contact PI
Autoantibodies Against Glycopeptide Epitopes as Serum Biomarkers of Cancer$279,165
U01 · FY2009 · CA · contact PI
Studies on the Post-translational processing of MUC1$263,177
R01 · FY2009 · CA · contact PI
P-1: Immunotherapy of Pancreatic Adenocarcinoma$135,097
P50 · FY2009 · CA · contact PI
CA: Administration Core$124,952
P50 · FY2009 · CA · contact PI
Diversificiation of MUC1 Function by Alternate Splicing in Pancreatic Cancer$74,250
R03 · FY2009 · CA · contact PI
SPORE in Gastrointestinal Cancer$1,066,666
P50 · FY2008 · CA · contact PI
Early Diagnosis of Pancreatic Cancer$692,241
U01 · FY2008 · CA · contact PI
Autoantibodies Against Glycopeptide Epitopes as Serum Biomarkers of Cancer$271,036
U01 · FY2008 · CA · contact PI
Studies on the Post-translational processing of MUC1$263,177
R01 · FY2008 · CA · contact PI
CORE--Molecular Biology$222,471
P30 · FY2008 · CA · contact PI
P-1: Immunotherapy of Pancreatic Adenocarcinoma$94,756
P50 · FY2008 · CA · contact PI
CA: Administration Core$87,530
P50 · FY2008 · CA · contact PI
Diversificiation of MUC1 Function by Alternate Splicing in Pancreatic Cancer$74,250
R03 · FY2008 · CA · contact PI
Early Diagnosis of Pancreatic Cancer$672,897
U01 · FY2007 · CA · contact PI
Autoantibodies Against Glycopeptide Epitopes as Serum Biomarkers of Cancer$291,845
U01 · FY2007 · CA · contact PI
CORE--Molecular Biology$260,929
P30 · FY2007 · CA · contact PI
Early Diagnosis of Pancreatic Cancer$673,653
U01 · FY2006 · CA · contact PI
Studies on the Post Translational Processing of MUC1$255,511
R01 · FY2006 · CA · contact PI
CORE--Molecular Biology$104,272
P30 · FY2006 · CA · contact PI
Studies on the Post Translational Processing of MUC1$5,512
R01 · FY2006 · CA · contact PI
Early Diagnosis of Pancreatic Cancer$804,197
U01 · FY2005 · CA
Studies on the Post Translational Processing of MUC1$261,660
R01 · FY2005 · CA
CORE--Molecular Biology$101,235
P30 · FY2005 · CA
Studies on the Post Translational Processing of MUC1$6,059
R01 · FY2005 · CA
Early Diagnosis of Pancreatic Cancer$527,186
U01 · FY2004 · CA
Studies on the Post Translational Processing of MUC1$261,660
R01 · FY2004 · CA
SPORE IN GASTOINTESTINAL CANCER$250,000
P50 · FY2004 · CA
CORE--Molecular Biology$98,286
P30 · FY2004 · CA
Studies on the Post Translational Processing of MUC1$7,688
R01 · FY2004 · CA
Studies on the Post Translational Processing of MUC1$261,660
R01 · FY2003 · CA
Studies on the Post Translational Processing of MUC1$6,916
R01 · FY2003 · CA
SPORE IN GASTOINTESTINAL CANCER$1,500,000
P50 · FY2002 · CA
MOLECULAR STUDIES ON MUC1 PROMOTER$304,618
R01 · FY2002 · CA
Studies on the Post Translational Processing of MUC1$284,206
R01 · FY2002 · CA
IMMUNOTHERAPY AND IMMUNODIAGNOSIS OF PANCREATIC ADENOCARCINOMA$201,603
P50 · FY2002 · CA
CORE--MOLECULAR BIOLOGY$0
P30 · FY2002 · CA
SPORE IN GASTOINTESTINAL CANCER$1,781,425
P50 · FY2001 · CA
MOLECULAR STUDIES ON MUC1 PROMOTER$299,771
R01 · FY2001 · CA
IMMUNOTHERAPY AND IMMUNODIAGNOSIS OF PANCREATIC ADENOCARCINOMA$201,603
P50 · FY2001 · CA
MOLECULAR STUDIES ON MUC1 PROMOTER$4,148
R01 · FY2001 · CA
CORE--MOLECULAR BIOLOGY$0
P30 · FY2001 · CA
SPORE IN GASTOINTESTINAL CANCER$1,831,625
P50 · FY2000 · CA
MOLECULAR STUDIES ON MUC1 PROMOTER$291,039
R01 · FY2000 · CA
MOLECULAR ANALYSIS OF MUCIN TYPE O GLYCOSYLATION$253,691
R01 · FY2000 · CA
IMMUNOTHERAPY AND IMMUNODIAGNOSIS OF PANCREATIC ADENOCARCINOMA$201,603
P50 · FY2000 · CA
CORE--MOLECULAR BIOLOGY$0
P30 · FY2000 · CA